Device Trial Radar · NCT05923827
Omnipod® 5 With Libre 2 vs. MDI for Type 1 Diabetes in Children and Adults
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
189
Actual
Start
Sep 11, 2023
Primary completion
Aug 16, 2024
Study completion Feb 12, 2026
Sponsor
- Lead sponsor
- Insulet CorporationPublic (PODD)
- Sponsor type
- Industry
- First posted
- Jun 28, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 4 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, controlled trial to evaluate the efficacy and safety of the Omnipod® 5 System with the FreeStyle Libre 2 continuous glucose monitor compared to Multiple Daily Injections (MDI) along with the FreeStyle Libre 2 continuous glucose monitor in children and adults with type 1 diabetes.
Conditions
- Diabetes Mellitus, Type 1
Interventions
Omnipod 5 SystemDevice
The Omnipod 5 system is a tubeless patch pump that receives glucose values and trend data from the glucose sensor every 5 minutes, automatically calculates insulin dose, and sends delivery commands to the Pod for the delivery of insulin.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1c (%)Time frame: Comparing intervention group with control group during the 13-week study phase
Locations
19 sites in 3 countries. Site status is shown where the registry gives one.
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Universitaire Ziekenhuizen Leuven
Leuven, Belgium
Centre Hospitalier Universitaire Côte de Nacre
Caen, France
16 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.